% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Toualbi:285071,
author = {L. Toualbi and M. Toms and P. V. Almeida$^*$ and R.
Harbottle$^*$ and M. Moosajee},
title = {{G}ene {A}ugmentation of {CHM} {U}sing {N}on-{V}iral
{E}pisomal {V}ectors in {M}odels of {C}horoideremia.},
journal = {International journal of molecular sciences},
volume = {24},
number = {20},
issn = {1422-0067},
address = {Basel},
publisher = {Molecular Diversity Preservation International},
reportid = {DKFZ-2023-02214},
pages = {15225},
year = {2023},
abstract = {Choroideremia (CHM) is an X-linked chorioretinal dystrophy
leading to progressive retinal degeneration that results in
blindness by late adulthood. It is caused by mutations in
the CHM gene encoding the Rab Escort Protein 1 (REP1), which
plays a crucial role in the prenylation of Rab proteins
ensuring correct intracellular trafficking. Gene
augmentation is a promising therapeutic strategy, and there
are several completed and ongoing clinical trials for
treating CHM using adeno-associated virus (AAV) vectors.
However, late-phase trials have failed to show significant
functional improvements and have raised safety concerns
about inflammatory events potentially caused by the use of
viruses. Therefore, alternative non-viral therapies are
desirable. Episomal scaffold/matrix attachment region
(S/MAR)-based plasmid vectors were generated containing the
human CHM coding sequence, a GFP reporter gene, and
ubiquitous promoters (pS/MAR-CHM). The vectors were assessed
in two choroideremia disease model systems: (1) CHM
patient-derived fibroblasts and (2) chmru848 zebrafish,
using Western blotting to detect REP1 protein expression and
in vitro prenylation assays to assess the rescue of
prenylation function. Retinal immunohistochemistry was used
to investigate vector expression and photoreceptor
morphology in injected zebrafish retinas. The pS/MAR-CHM
vectors generated persistent REP1 expression in CHM patient
fibroblasts and showed a significant rescue of prenylation
function by $75\%,$ indicating correction of the underlying
biochemical defect associated with CHM. In addition, GFP and
human REP1 expression were detected in zebrafish
microinjected with the pS/MAR-CHM at the one-cell stage.
Injected chmru848 zebrafish showed increased survival,
prenylation function, and improved retinal photoreceptor
morphology. Non-viral S/MAR vectors show promise as a
potential gene-augmentation strategy without the use of
immunogenic viral components, which could be applicable to
many inherited retinal disease genes.},
keywords = {Animals / Humans / Adult / Choroideremia: genetics /
Choroideremia: therapy / Choroideremia: metabolism /
Zebrafish: genetics / Zebrafish: metabolism / Retina:
metabolism / Mutation / Retinal Dystrophies: metabolism /
Plasmids / Adaptor Proteins, Signal Transducing: genetics /
Adaptor Proteins, Signal Transducing: metabolism / S/MAR
(Other) / choroideremia (Other) / inherited retinal disease
(Other) / non-viral gene therapy (Other) / CHM protein,
human (NLM Chemicals) / Adaptor Proteins, Signal Transducing
(NLM Chemicals)},
cin = {F160},
ddc = {540},
cid = {I:(DE-He78)F160-20160331},
pnm = {316 - Infektionen, Entzündung und Krebs (POF4-316)},
pid = {G:(DE-HGF)POF4-316},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:37894906},
pmc = {pmc:PMC10607001},
doi = {10.3390/ijms242015225},
url = {https://inrepo02.dkfz.de/record/285071},
}